Action HARP HARPOON THERAPEUTICS, INC.
Ajouter à une liste
Pour utiliser cette fonction vous devez être client ou membre
ConnexionInscription
Instrument Inactif

Communiqués Harpoon Therapeutics, Inc.

Actions

HARP

US41358P2056

Communiqués

Recherche
Voir les résultats
Débloquez toutes les actualités sur toutes les entreprises : Ne manquez plus une opportunité d'investissement rentable !
Inscription 100% Gratuite
Harpoon Therapeutics : June 3, 2024
PU
Harpoon Therapeutics : April 3, 2024
PU
Harpoon Therapeutics : March 6, 2024
PU
Merck To Buy Harpoon Therapeutics For $680 Million
AQ
SHAREHOLDER RIGHTS INVESTIGATION: Halper Sadeh LLC Investigates AMAM, AXNX, HARP, GRCL
PR
HARPOON THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Harpoon Therapeutics, Inc. - HARP
BU
Boeing, Alaska Air Group fall; Harpoon Therapeutics, Axonics rise, Monday, 1/8/2024
AQ
SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates HARP, AMAM, AXNX
PR
Shareholder Alert: Ademi LLP investigates whether Harpoon Therapeutics, Inc. has obtained a Fair Price in its transaction with Merck
PR
HARP Alert: Monsey Firm of Wohl & Fruchter Investigating Fairness of the Sale of Harpoon Therapeutics to Merck
AQ
HARP Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Harpoon Therapeutics, Inc. Is Fair to Shareholders
BU
Harpoon Therapeutics Strengthens Leadership Team
AQ
Harpoon Therapeutics Abstract for HPN328 Accepted for Rapid Oral Presentation at the 2024 American Society of Clinical Oncology Genitourinary Cancers Symposium
AQ
Harpoon Therapeutics Presents HPN217 Phase 1 Clinical Data in Relapsed/Refractory Multiple Myeloma (RRMM) at ASH 2023 and Announces Selection of Recommended Phase 2 Dose (RP2D)
AQ
Harpoon Therapeutics : Material Event - Form 8-K
PU
Harpoon Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update
AQ
Harpoon Therapeutics Abstract for HPN217 Accepted for Presentation at the 65th American Society of Hematology (ASH) Annual Meeting and Exposition
AQ
Harpoon Therapeutics : ESMO 2023 Virtual Investor Webcast Presentation – October 2023
PU
Harpoon Therapeutics Announces Updated Interim Tolerability and Response Data from Phase 1/2 Clinical Trial of T Cell Engager Hpn328 at Esmo Congress 2023
AQ
Harpoon Therapeutics Announces Up to $150 Million Private Placement
AQ
Aucun résultat pour cette recherche
Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Filtres

Rechercher

Date de publication

Depuis le

Jusqu'au

  1. Bourse
  2. Actions
  3. Action HARP
  4. Actualités Harpoon Therapeutics, Inc.
  5. Communiqués